AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Small ribosomal subunit protein eS19

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P39019

UPID:

RS19_HUMAN

Alternative names:

40S ribosomal protein S19

Alternative UPACC:

P39019

Background:

Small ribosomal subunit protein eS19, also known as 40S ribosomal protein S19, plays a crucial role in protein synthesis. It is a component of the small ribosomal subunit, essential for pre-rRNA processing and the maturation of 40S ribosomal subunits. This protein is involved in the intricate process of assembling the SSU processome in the nucleolus, facilitating RNA folding, modifications, and cleavage.

Therapeutic significance:

The association of Small ribosomal subunit protein eS19 with Diamond-Blackfan anemia 1, a congenital non-regenerative hypoplastic anemia, underscores its therapeutic significance. Understanding the role of this protein could lead to novel therapeutic strategies for treating this form of anemia, which is characterized by macrocytic anemia, erythroblastopenia, and an increased leukemia risk.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.